|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 5 (March 1), 1999:
pp. 1724-1731
The Somatostatin Analog Octreotide Inhibits Growth of Interleukin-6
(IL-6)-Dependent and IL-6-Independent Human Multiple Myeloma Cell
Lines
Patrik Georgii-Hemming,
Thomas Strömberg,
Eva Tiensuu Janson,
Mats Stridsberg,
Helena Jernberg Wiklund, and
Kenneth Nilsson
From the Department of Genetics and Pathology and Department of
Medical Sciences, University Hospital, Uppsala, Sweden.
Somatostatin and its analogs can inhibit growth in several cell
types, in part by interfering with insulin-like growth factor-I (IGF-I)
signaling. Our previous studies point to the importance of paracrine
and autocrine IGF-I in the support of growth and survival of human
multiple myeloma (MM) cell lines. In this report, we have investigated
the potential role of a somatostatin analog, octreotide, in regulating
growth and/or survival in MM. The results show that all MM cell
lines express functional somatostatin receptors (sst). The MM cell
lines express the subtypes sst2, sst3, and predominantly sst5 as determined by reverse-transcriptase
polymerase chain reaction and fluorescence-activated cell sorter
analysis. Octreotide inhibited the growth of both the interleukin-6
(IL-6)-dependent and the IL-6-independent MM cell lines. The effect
is mainly cytostatic, resulting in 25% to 45% growth inhibition, and
in three of eight of the MM cell lines a weak induction of apoptosis
was recorded. Our results also show that octreotide may act as an
inducer of apoptosis in primary B-B4+ plasma cells
isolated from bone marrow of MM patients. In conclusion, the results
show a novel pathway for growth inhibition of MM cells: the activation
of somatostatin receptor signaling.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Q. Lacy, M. Alsina, R. Fonseca, M. L. Paccagnella, C. L. Melvin, D. Yin, A. Sharma, M. Enriquez Sarano, M. Pollak, S. Jagannath, et al.
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
J. Clin. Oncol.,
July 1, 2008;
26(19):
3196 - 3203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Moreaux, F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, et al.
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
Blood,
August 1, 2005;
106(3):
1021 - 1030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Duet, P. Tran Ba Huy, M. Wassef, and F. Liote
Plasma Cell Problems: CASE 3. Plasmacytoma Mimicking a Paraganglioma of the Skull Base: Diagnostic Value of Somatostatin Receptor Scintigraphy
J. Clin. Oncol.,
May 1, 2005;
23(13):
3143 - 3145.
[Full Text]
[PDF]
|
|
|
|
|
